QFA
SPRY icon

Quattro Financial Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Quattro Financial Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,869
Closed -$68K – 91
2022
Q3 		$68K Hold
12,869
– – 0.03% 83
2022
Q2 		$55K Hold
12,869
– – 0.02% 83
2022
Q1 		$45K Hold
12,869
– – 0.02% 80
2021
Q4 		$86K Buy
+12,869
New +$105K 0.03% 97

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Quattro Financial Advisors's SPRY Position: Q4 2022 in Review

Quattro Financial Advisors sold out of ARS Pharmaceuticals (SPRY) in Q4 2022, closing a stake of 12,869 shares — an estimated $68K sold.

Quattro Financial Advisors first reported a position in SPRY in Q4 2021 and held it in 4 quarters. The position peaked at $86K in Q4 2021. 73 funds tracked by Wall St. Rank hold SPRY as of Q4 2022.

  • Quattro Financial Advisors reported no remaining ARS Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Quattro Financial Advisors sold 12,869 ARS Pharmaceuticals shares in Q4 2022, an estimated $68K.
  • Quattro Financial Advisors first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Quattro Financial Advisors's ARS Pharmaceuticals position peaked at $86K in Q4 2021.
  • 73 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2022.

Based on Quattro Financial Advisors's 13F filing for Q4 2022, filed 23 Jan 2023.